Business
Keymed Biosciences Announces 2025 Annual Results and Business Updates
Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization.
About this update from Keymed Biosciences, Inc.
[{"type":"text","content":"BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization.","length":230,"tagName":"p"},{"type":"text","content":"Revenue Leaps Forward, Supporting Long-Term Stable Growth","length":57,"tagName":"p"},{"type":"text","content":"Since its founding in 2016, Keymed has built a pipeline of over 50 programs, with more than 10 in clinical development, three indications successfully launched, six core technology platforms continuously upgraded, over 10 external partnerships established, and planned production capacity exceeding 100,000 liters.","length":314,"tagName":"p"},{"type":"text","content":"In terms of financial performance, the company achieved a significant revenue increase. Total revenue in 2025 was approximately RMB 720 million, a 67% year-on-year increase. This included around RMB 310 million from sales of the core product Kangyueda® and approximately RMB 410 million from collaboration income. The company maintained steady R&D investment, with R&D expenses of approximately RMB 720 million. As of December 31, 2025, cash reserves stood at approximately RMB 1.96 billion, providing ample funding to support core pipeline development and long-term business growth.","length":591,"tagName":"p"},{"type":"text","content":"Core Product Commercialization in Full Swing, Continuous Expansion of Indication Footprint","length":90,"tagName":"p"},{"type":"text","content":"As of the date of this announcement, the new drug applications of Kangyueda® for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, chronic rhinosinusitis with nasal polyps (CRSwNP) and seasonal allergic rhinitis (SAR) have been approved by the National Medical Products Administration (NMPA). Since January 2026, all launched indications of Kangyueda® and both of its packaging forms (vials and pre-filled auto-injector pens) have been included in the National Reimbursement Drug List of China, significantly enhancing affordability and accessibility for Chinese patients.","length":597,"tagName":"p"},{"type":"text","content":"During the Reporting Period, revenue for sales of Kangyueda® amounted to approximately RMB310 million. In January 2026, the new drug applications for St...